

Subt. For. PTO-1449

**COPY**

Docket Number

103576.166

Application Number

~~09/460,293~~**INFORMATION DISCLOSURE  
IN AN APPLICATION**

(Use several sheets if necessary)

Applicant

Chen, Zhijian H.

Filing Date

~~September 24, 1999~~

Group Art Unit

1652

Sheet

1

OF

5

**U.S. Patent Documents**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
---------------------	--------------------	------	------	-------	----------	-------------------------------

**Foreign Patent Documents**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

**Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)**

CA	A1	Alkalay, et al., "In Vitro Stimulation of I $\kappa$ B Phosphorylation Is Not Sufficient to Activate NF- $\kappa$ B", <i>Mol. Cell. Biol.</i> , Vol. 15, No. 3, pp. 1294-1304 (1995)
CA	A2	Alkalay, et al., "Stimulation-Dependent I $\kappa$ B- $\alpha$ Phosphorylation Marks the NF- $\kappa$ B Inhibitor for Degradation via the Ubiquitin-Proteasome Pathway" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 10599-10603 (1995)
CA	A3	Arason and Ellison, "Stress Resistance in <i>Saccharomyces cerevisiae</i> Is Strongly Correlated with Assembly of a Novel Type of Multiubiquitin Chain" <i>Mol. Cell. Biol.</i> , Vol. 14, No. 12, pp. 7876-7883 (1994)
CA	A4	Auffray, et al., "IMAGE: Integrated Molecular Analysis of the Human Genome and Its Expression" <i>Sciences</i> , Vol. 318, pp. 263-272 (1995)
CA	A5	Auphan et al., "Immunosuppression by Glucocorticoids: Inhibition of NF- $\kappa$ B Activity Through Induction of I $\kappa$ B Synthesis" <i>Science</i> , Vol. 270, pp. 286-290 (1995)
CA	A6	Baeuerle and Henkel, "Function and Activation of NF- $\kappa$ B in the Immune System" <i>Annu. Rev. Immunol.</i> , Vol. 12, pp. 141-179 (1994)
CA	A7	Baldi, et al., "Critical Role for Lysines 21 and 22 in Signal-Induced, Ubiquitin-Mediated Proteolysis of I $\kappa$ B- $\alpha$ " Vol. 271, No. 1, pp. 376-379 (1996)
CA	A8	Barroga et al., "Constitutive Phosphorylation of I $\kappa$ B- $\alpha$ by Casein Kinase II" <i>Proc. Natl. Acad. Sci.</i> , Vol. 92, pp. 7637-7641 (1995)
CA	A9	Beg, et al., "Tumor Necrosis Factor and Interleukin-1 Lead to Phosphorylation and Loss of I $\kappa$ B- $\alpha$ : a Mechanism for NF- $\kappa$ B Activation." <i>Mol. Cell. Biol.</i> pp. 3301-3310 (1993)
CA	A10	Belvin, et al., "Cactus Protein Degradation Mediates Drosophila Dorsal-Ventral Signaling" <i>Genes and Dev.</i> , Vol. 9, pp. 783-793 (1995)
CA	A11	Blank, et al., "Molecular Cloning of Mitogen-activated Protein/ERK Kinase Kinases (MEKK) 2 and 3" <i>J. Biol. Chem.</i> , Vol. 271, No. 10, pp. 5361-5368 (1996)
CA	A12	Brockman, J.A., "Coupling of a Signal Response Domain in I $\kappa$ B- $\alpha$ to Multiple Pathways for NF- $\kappa$ B Activation" <i>Mol. Cell. Biol.</i> , Vol. 15, No. 5 (1995), 2809-2818
CA	A13	Brown, et al., "Control of I $\kappa$ B- $\alpha$ Proteolysis by Site-Specific, Signal-Induced Phosphorylation" <i>Science</i> , Vol. 267, pp. 1485-1488 (1995)
CA	A14	Chau, "A Multiubiquitin Chain is Confined to Specific Lysine in a Targeted Short-Lived Protein" <i>Science</i> , Vol. 243, pp. 1576-1583 (1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation is considered, whether or not citation is in conformance with MPEP § 609. Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.


Subt. For, PTO-1449				Docket Number 103576.166		Application Number 09/460,293 10/8/07/47	
<b>INFORMATION DISCLOSURE IN AN APPLICATION</b>  (Use several sheets if necessary)				Applicant Chen, Zhijian H.			
				Filing Date September 24, 1999		Group Art Unit 1652	
Sheet	2	OF	5				

B1	Chen, et al., "Multiple Ubiquitin-Conjugating Enzymes Participate in the In Vivo Degradation of the Yeast MATa2 Repressor" <i>Cell</i> , Vol. 74, pp. 357-369 (1993)
B2	Chen, et al., "Signal-Induced Site-Specific Phosphorylation Targets IκB-α to the Ubiquitin-Proteasome Pathway" <i>Genes and Dev.</i> , Vol. 9, pp. 1586-1597 (1995)
B3	Chen, et al., "Site-Specific Phosphorylation of IκB-α by a Novel Ubiquitination-Dependent Protein Kinase Activity" <i>Cell</i> , Vol. 84 (1996) 853-862
B4	Chen and Pickart, "A 25-Kilodalton Ubiquitin Carrier Protein (E2) Catalyzes Multi-ubiquitin Chain Synthesis via Lysine 48 of Ubiquitin" <i>J. Biol. Chem.</i> , Vol. 265, No. 35, pp. 21835-21842 (1990)
B5	Choi, et al., "Ste5 Tethers Multiple Protein Kinases in the MAP Kinase Cascade Required for Mating in <i>S. cerevisiae</i> " <i>Cell</i> , Vol. 78, pp. 499-512 (1994)
B6	Ciechanover, "The Ubiquitin-Proteasome Proteolytic Pathway" <i>Cell</i> , Vol. 79, pp. 13-21 (1994)
B7	Derijard, et al., "Independent Human MAP Kinase Signal Transduction Pathways Defined by MEK and MKK Isoforms" <i>Science</i> , Vol. 267, pp. 682-685 (1995)
B8	Derijard, et al., "JNK1: A Protein Kinase Stimulated by UV Light and Ha-Ras That Binds and Phosphorylates the c-Jun Activation Domain" <i>Cell</i> , Vol. 76, pp. 1025-1037 (1994)
B9	Devary, et al., "NF-κB Activation by Ultraviolet Light Not Dependent on a Nuclear Signal" <i>Science</i> , Vol. 261, pp. 1442-1445 (1993)
B10	Diaz-Meco, "ζPKC Induces Phosphorylation and Inactivation of I kappa B-alpha In Vitro" <i>EMBO J.</i> , Vol. 13, No. 12, pp. 2842-2848 (1994)
B11	DiDonato, et al., "Phosphorylation of IκBα Precedes but IS Not Sufficient for Its Dissociation from NF-κB" <i>Mol. cell. Biol.</i> , Vol. 15, No. 3, pp. 1302-1311 (1995)
B12	Dominguez, et al., "Inhibition of Protein Kinase C ζ Subspecies Blocks the Activation of an NF-κB-like activity in <i>Xenopus Laevis</i> Oocytes" <i>Mol. Cell. Biol.</i> , Vol. 13, No. 2, pp. 1290-1295 (1993)
B13	Finco, et al., "Inducible phosphorylation of IκBα is not sufficient for its dissociation from NF-κB and is inhibited by protease inhibitors" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 11884-11888 (1994)
B14	Finco and Baldwin, "κB Site-Dependent Induction of Gene Expression by Diverse Inducers of Nuclear Factor κB Requires Raf-1", <i>J. Biol Chem.</i> , Vol. 268, No. 24, pp. 17676-17679 (1993)
B15	Finco and Baldwin, "Mechanistic Aspect of NF-κB Regulation: The Emerging Role of Phosphorylation and Proteolysis" <i>Immunity</i> , Vol. 3, pp. 263-272 (1995)
B16	Francis and Corbin, "Structure and Function of Cyclic Nucleotide-dependent Protein Kinases" <i>Annu. Rev. Physiol.</i> , Vol. 56, pp. 237-72 (1994)
B17	Ghosh and Baltimore, "Activation In vitro of NF-κB by Phosphorylation of its Inhibitor IκB" <i>Nature</i> , Vol. 344, pp. 678-682 (1990)
B18	Goldberg, Alfred L., "Functions of the Proteasome: The Lysis at the End of the Tunnel" <i>Science</i> , Vol. 268, pp. 522-523 (1995)

EXAMINER <i>C. Haller</i>	DATE CONSIDERED 5/18/06
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	


Subt For, PTO-1449			Docket Number <del>103576-166</del>		Application Number <del>09/460-293</del> 10/8/07	
<b>INFORMATION DISCLOSURE IN AN APPLICATION</b>  (Use several sheets if necessary)			Applicant <b>Chen, Zhijian H.</b>			
			Filing Date <b>September 24, 1999</b>		Group Art Unit <b>1652</b>	
Sheet	<b>3</b>	OF	<b>5</b>			

C1	Gupta, et al., "Transcription Factor ATF2 Regulation by the JNK Signal Transduction Pathway" <i>Science</i> , Vol. 267, pp. 389-393 (1995)
C2	Haskill, et al., "Characterization of an Immediate-Early Gene Induced in Adherent Monocytes that Encodes I $\kappa$ B-like Activity" <i>Cell</i> , Vol. 65, pp. 1281-1289 (1991)
C3	Henkel, et al., "Rapid Proteolysis of I $\kappa$ B- $\alpha$ is Necessary for Activation of Transcription Factor NF- $\kappa$ B" <i>Nature</i> , Vol. 365, pp. 182-185 (1993)
C4	Hershko and Heller, "Occurrence of a Polyubiquitin Structure in Ubiquitin-Protein Conjugates" <i>Biochem. Biophys. Res. Commun.</i> , Vol. 128, No. 3, pp. 1079-1086 (1985)
C5	Hershko and Ciechanover, "The Ubiquitin System for Protein Degradation" <i>Annu. Rev. Biochem.</i> , Vol. 61, pp. 761-807 (1992)
C6	Hibi, et al., "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain" <i>Genes and Dev.</i> , Vol. 7, pp. 2135-2148 (1993)
C7	Higgins, et al., "Antisense inhibition of the p65 subunit of NF- $\kappa$ B blocks tumorigenicity and causes tumor regression" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 90, pp. 9901-9905 (1993)
C8	Hirano, et al., "MEK Kinase Is Involved in Tumor Necrosis Factor $\alpha$ -Induced NF- $\kappa$ B Activation and Degradation of I $\kappa$ B- $\alpha$ " <i>J. Biol. Chem.</i> , Vol. 271, No. 22, pp. 13234-13238 (1996)
C9	Kumar, A., et al., "Double-Stranded RNA-Dependent Protein Kinase Activates Transcription Factor NF- $\kappa$ B by Phosphorylating I $\kappa$ B" <i>Proc. Natl. Acad. Sci. USA</i> Vol. 91, pp. 6288-6292 (1994)
C10	Kuno, et al., "Identification of an I $\kappa$ B- $\alpha$ - Associated Protein Kinase in a Human Monocytic Cell Line and Determination of its Phosphorylation Sites on I $\kappa$ B- $\alpha$ " <i>J. Biol. Chem.</i> Vol. 270, No. 46, pp. 27914-27919 (1995)
C11	Lange-Carter, et al., "A Divergence in the MAP Kinase Regulatory Network Defined by MEK Kinase and Raf" <i>Science</i> , Vol. 260, pp. 315-319 (1993)
C12	Li and Sedivy "Raf-1 Protein Kinase Activates the NF- $\kappa$ B Transcription Factor By Disassociating the Cytoplasmic NF- $\kappa$ B-I $\kappa$ B complex" <i>Proc Natl Acad Sci USA</i> , Vol. 90, pp. 9247-9251 (1993)
C13	Lin, et al., "Activation of NF- $\kappa$ B requires proteolysis of the inhibitor I $\kappa$ B- $\alpha$ : Signal-induced phosphorylation of I $\kappa$ B- $\alpha$ alone does not release active NF- $\kappa$ B" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 92, pp. 552-556, (1995)
C14	Lin and Desiderio, "Regulation of V(D)J Recombination Activator Protein RAG-2 by Phosphorylation" <i>Science</i> , Vol. 260; pp. 953-959 (1993)
C15	Mellits, et al., "Proteolytic degradation of MAD3 (I $\kappa$ B $\alpha$ ) and enhanced processing of the NF- $\kappa$ B precursor p105 are obligatory steps in the activation of NF- $\kappa$ B" <i>Nucl. Acid. Res.</i> , Vol. 21, No. 22, pp. 5059-5066 (1993)
C16	Miyamoto, et al., "Tumor necrosis factor $\alpha$ -induced phosphorylation of I $\kappa$ B $\alpha$ is a signal for its degradation but not dissociation from NF- $\kappa$ B" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 12740-12744 (1994)

EXAMINER 	DATE CONSIDERED 5/8/06
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

Subt. For, PTO-1449				Docket Number 103576.166		Application Number 09/460,293	
<b>INFORMATION DISCLOSURE IN AN APPLICATION</b>  (Use several sheets if necessary)				Applicant Chen, Zhijian H.			
				Filing Date September 24, 1999		Group Art Unit 1652	
Sheet	4	OF	5				


D1	Nishizawa, M., et al., "Degradation of MOS by the N-terminal Proline-(Pro2)-Dependent Ubiquitin Pathway on Fertilization of Xenopus Eggs: Possible Significance of Natural Selection for Pro2 in MOS" <i>EMBO J.</i> , Vol. 12, No. 10, pp. 4021-4027 (1993)
D2	Palombella, et al., "The Ubiquitin-Proteasome Pathway is Required For Processing the NF- $\kappa$ B1 Precursor Protein and the Activation of NF- $\kappa$ B" <i>Cell</i> , Vol. 78, pp. 773-785 (1994)
D3	Pawlak, et al., "Characterization of a Large Population of mRNAs From Human Testis" <i>Genomics</i> , Vol. 26, pp. 151-158 (1995)
D4	Pickart and Rose, "Functional Heterogeneity of Ubiquitin Carrier Proteins" <i>J. Biol. Chem.</i> , Vol. 260, No. 3, pp. 1573-1581 (1985)
D5	Read, et al., "The Proteasome Pathway Is Required for Cytokine-Induced Endothelial-Leukocyte Adhesion Molecule Expression" <i>Immunity</i> , Vol. 2, pp. 493-506 (1995)
D6	Rodriguez, M.S., et al., "Inducible Degradation of I $\kappa$ B $\alpha$ In Vitro and In Vivo Requires the Acidic C-Terminal Domain of the Protein" <i>Mol. Cell. Biol.</i> , Vol. 15(5), pp. 2413-2419 (1995)
D7	Scherer, et al., "Signal-Induced Degradation of I $\kappa$ B- $\alpha$ requires site-specific Ubiquitination" <i>Natl. Acad. Sci. USA</i> , Vol. 92, pp. 11259-11263 (1995)
D8	Schreck, et al., "Reactive Oxygen Intermediates as Apparently Widely Used Messengers in the Activation of the NF- $\kappa$ B Transcription Factor and HIV-1" <i>EMBO J.</i> , Vol. 10 No. 8, pp. 2247-2258 (1991)
D9	Schutze, et al., "TNF Activates NF-kappa B by Phosphatidylcholine-Specific Phospholipase C-Induced "Acidic" Sphingomyelin Breakdown" <i>Cell</i> , Vol. 71 pp.765-777
D10	Siebenlist, et al., "Structure, Regulation and Function of NF- $\kappa$ B" <i>Annu. Rev. Cell Biol.</i> , Vol. 10, pp. 405-455 (1994)
D11	Sun, et al., "NF- $\kappa$ B Controls Expression of Inhibitor I $\kappa$ B- $\alpha$ : Evidence For An Inducible Autoregulatory Pathway", <i>Science</i> , Vol. 259, pp. 1912-1915 (1993)
D12	Thanos and Maniatis, "NF- $\kappa$ B: A Lesson in Family Values" <i>Cell</i> , Vol. 80, pp. 529-532 (1995)
D13	Thévenin, et al., "Induction of Nuclear Factor- $\kappa$ B and the Human Immunodeficiency Virus Long Terminal Repeat by Okadaic Acid, A Specific Inhibitor of Phosphatases 1 and 2A" <i>New Biol.</i> , Vol. 2, pp. 793-800 (1990)
D14	Traenckner et al., "A Proteasome Inhibitor Prevents Activation of NF- $\kappa$ B and Stabilizes a Newly Phosphorylated Form of I $\kappa$ B- $\alpha$ That is Still Bound to NF- $\kappa$ B" <i>EMBO J.</i> , Vol. 13, pp.5433-5441 (1994)
D15	Traenckner, E.B.-M., et al., "Phosphorylation of Human I $\kappa$ B- $\alpha$ on Serines 32 and 36 Controls I $\kappa$ B- $\alpha$ Proteolysis and NF- $\kappa$ B Activation in Response to Diverse Stimuli" <i>EMBO J.</i> , Vol. 14, No. 12, pp. 2876-2883 (1995)
D16	Verma, et al., "Rel/NF- $\kappa$ B/I $\kappa$ B Family: Intimate Tales of Association and Disassociation" <i>Genes and Dev.</i> , Vol. 9 pp. 2723-2735 (1995)
D17	Wasserman, "A Conserved Signal Transduction Pathway Regulating the Activity of the Rel-Like Proteins Dorsal and NF- $\kappa$ B" <i>Mol. Biol. Cell.</i> , Vol. 4, pp. 767-771 (1993)

EXAMINER 	DATE CONSIDERED 5/8/06
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

Subl For, PTO-1449		Docket Number 103576.166		Application Number <del>09/460,293</del> 10/8/99/243	
<b>INFORMATION DISCLOSURE IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>		Applicant <b>Chen, Zhijian H.</b>			
		Filing Date <b>September 24, 1999</b>		Group Art Unit <b>1652</b>	
Sheet	<b>5</b>	OF	<b>5</b>		

CP	E1	Whiteside, et al., "N- and C- Terminal Sequences Control Degradation of MAD3/ $\kappa$ B in Response to Inducers of NF- $\kappa$ B Activity" <i>Mol. Cell. Biol.</i> , Vol. 15, No. 10, pp. 5339-5345 (1995)
	E2	Yaglom, et al., "p34Cdc28-Mediated Control of Cln3 Cyclin Degradation" <i>Mol. Cell. Biol.</i> , Vol. 15, No. 2, pp. 731-741 (1995)
	E3	Yang, et al., "Deficient signaling in mice devoid of double-stranded RNA-dependent Protein kinase" <i>EMBO J.</i> , Vol. 14, No. 24, pp. 6095-6106 (1995)
	E4	EMBL Database entry Hs369288, Accession Number N56369, from International Search Report, International Application No. PCT/US97/04195 (1996)
CP	E5	EMBL Database entry Hs2038, Accession Number T19203, from International Search Report, International Application No. PCT/US97/04195 (1994)

anthony w. sutton - z:\legal\103576.166\1449.doc

EXAMINER 	DATE CONSIDERED 5/8/06
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

# COPY

Subt. Form PTO-1449  <b>INFORMATION DISCLOSURE IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>				Docket Number <b>103576.166</b>	Application Number <del>09/406,293</del> <b>10/816,793</b>
				Applicant <b>Chen</b>	
				Filing Date <del>September 24, 1999</del>	Group Art Unit <b>1652</b>
Sheet	<b>1</b>	OF	<b>1</b>		

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CA	5,972,674	10/26/99	Mercurio, et al.	435	194	
CA	6,258,579	7/10/01	Mercurio, et al.	435	194	
CA	6,268,194	7/31/01	Karin, et al.	435	194	
CA	6,242,253	6/5/01	Karin, et al.	435	325	

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
CA	98/08955	3/5/98	WO	—	—	YES	NO
CA	98/37228	8/27/98	WO	—	—		

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)	
CA	Lee, et al., "Activation of the I $\kappa$ B $\alpha$ Kinase Complex by MEKK1, a Kinase of the JNK Pathway" <i>Cell</i> , Vol. 88, pp: 213-222 (1997)

EXAMINER <div style="text-align: center; font-family: cursive; font-size: 1.2em;">C. Mullen</div>	DATE CONSIDERED <div style="text-align: center; font-family: cursive; font-size: 1.2em;">5/8/06</div>
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

Please type a plus sign (+) inside this box -



Approved for use through 10/31/99. PTO/SB/08B (10-96)

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/052,005 10/810,743
		Filing Date	January 17, 2002
		First Named Inventor	Chen, Zhijian J.
		Group Art Unit	1652
		Examiner Name	Patterson, Charles, L., Jr.
		Attorney Docket Number	MPI96-031CP1DV1CPACN1M
Sheet	1	of	5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
	A3	Amason, T. and Ellison, M.J., "Stress resistance in <i>Saccharomyces cerevisiae</i> is strongly correlated with assembly of a novel type of multiubiquitin chain", <i>Molecular and Cell Biology</i> , Volume 14, Number 12, pages 7876-7883 (1994)	
	A5	Auphan, N., et al., "Immunosuppression by Glucocorticoids: Inhibition of NF-kB Activity Through Induction of Ikb Synthesis" <i>Science</i> , Volume 270, pages 286-290 (1995)	
	A6	Baeuerle, P. and Henkel, T., "Function and Activation of NF-kB in the Immune System", <i>Annual Review of Immunology</i> , Volume 12, pages 141-179 (1994)	
CP	AT	Blank, J., et al., "Molecular Cloning of Mitogen-activated Protein/ERK Kinase Kinases (MEKK) 2 and 3", <i>The Journal of Biological Chemistry</i> , Volume 271, Number 10, pages 5361-5368 (1996)	
	BT	Chen, P., et al., "Multiple Ubiquitin-Conjugating Enzymes Participate in the In Vivo Degradation of the Yeast MATa2 Repressor", <i>Cell</i> , Volume 74, pages 357-369 (1993)	
	B4	Chen, Z., et al., "A 25-Kilodalton Ubiquitin Carrier Protein (E2) Catalyzes Multiubiquitin Chain Synthesis via Lysine 48 of Ubiquitin", <i>The Journal of Biological Chemistry</i> , Volume 265, Number 35, pages 21835-21842 (1990)	
	B5	Choi, K., et al., "Ste5 Tethers Multiple Protein Kinases in the MAP Kinase Cascade Required for Mating in <i>S. cerevisiae</i> ", <i>Cell</i> , Volume 78, pages 499-512 (1994)	
	B7	Derjard, B., et al., "Independent Human MAP Kinase Signal Transduction Pathways Defined by MEK and MKK Isoforms" <i>Science</i> , Volume 267, pages 682-685 (1995)	
	B8	Derjard, B., et al., "JNK1: A Protein Kinase Stimulated by UV Light and Ha-RAS That Binds and Phosphorylates the c-Jun Activation Domain", <i>Cell</i> , Volume 76, pages 1025-1037 (1994)	
	B71	DiDonato, J., et al., "Phosphorylation of Ikbα Precedes but Is Not Sufficient for Its Dissociation from NF-kB", <i>Molecular and Cellular Biology</i> , Volume 15, Number 3, pages 1302-1311 (1995)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box -



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	40/062005-201816/293
		Filing Date	January 17, 2002
		First Named Inventor	Chen, Zhijian J.
		Group Art Unit	1652
		Examiner Name	Patterson, Charles L., Jr.
Sheet 2 of 5	Attorney Docket Number	MPI96-031CP1DV1CPACN1M	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
	<del>813</del>	<del>Finco, T., et al., "Inducible phosphorylation of Ikb<math>\alpha</math> is not sufficient for its dissociation from NF-kB and is inhibited by protease inhibitors", Proceedings of the National Academy of Sciences USA, Volume 91, pages 11884-11888 (1994)</del>	
	<del>815</del>	<del>Finco, T., et al., "Mechanistic Aspects of NF-kB Regulation: The Emerging Role of Phosphorylation and Proteolysis", Immunity, Volume 3, pages 263-272 (1995)</del>	
	<del>816</del>	<del>Francis, S. and Corbin, D., "Structure and Function of Cyclic Nucleotide-Dependent Protein Kinases" Annual Review of Physiology, Volume 56, pages 237-272 (1994)</del>	
	<del>818</del>	<del>Goldberg, A., "Functions of the Proteasome: The Lysis at the End of the Tunnel", Science, Volume 268, pages 522-523 (1995)</del>	
	<del>819</del>	<del>Gupta, S., et al., "Transcription Factor ATF2 Regulation by the JNK Signal Transduction Pathway", Science, Volume 267, pages 389-392 (1995)</del>	
	<del>820</del>	<del>Haskill, S., et al., "Characterization of an Immediate-Early Gene Induced in Adherent Monocytes That Encodes Ikb-like Activity", Cell, Volume 65, pages 1281-1289 (1991)</del>	
	<del>821</del>	<del>Hershko, A. and Heller, H., "Occurrence of a Polyubiquitin Structure in Ubiquitin-Protein Conjugates", Biochemical and Biophysical Research Communications, Volume 128, Number 3, pages 1079-1086 (1985)</del>	
	<del>822</del>	<del>Hibi, M., et al., "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain" Genes and Development, Volume 7, pages 2135-2148 (1993)</del>	
	<del>823</del>	<del>Higgins, K., et al., "Antisense inhibition of the p65 subunit of NF-kB blocks tumorigenicity and causes tumor regression", Proceedings of the National Academy of Sciences USA, Volume 90, pages 9901-9905 (1993)</del>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Please type a plus sign (+) inside this box -



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/052005-10/10/743
		Filing Date	January 17, 2002
		First Named Inventor	Chen, Zhijian J.
		Group Art Unit	1652
		Examiner Name	Patterson, Charles L., Jr.
		Attorney Docket Number	MPI96-031CP1DV1CPACN1M
Sheet	3	of	5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
<del>BE</del>	<del>28</del>	<del>Hirano, M., et al., "MEK-Kinase Is Involved in Tumor Necrosis Factor <math>\alpha</math>-Induced NF-<math>\kappa</math>B Activation and Degradation of I<math>\kappa</math>B-<math>\alpha</math>", The Journal of Biological Chemistry, Volume 217, Number 22, pages 13234-13238 (1996)</del>	
<del>BE</del>	<del>341</del>	<del>Lange-Carter, C.A., et al., "A Divergence in the MAP Kinase Regulatory Network Defined by MEK Kinase and Raf", Science, Volume 260, pages 315-319 (1993)</del>	
<del>BE</del>	<del>345</del>	<del>Lin, Y.-G., et al., "Activation of NF-<math>\kappa</math>B requires proteolysis of the inhibitor I<math>\kappa</math>B-<math>\alpha</math>: Signal-induced phosphorylation of I<math>\kappa</math>B-<math>\alpha</math> alone does not release active NF-<math>\kappa</math>B", Proceedings of the National Academy of Sciences USA, Volume 92, pages 552-556 (1995)</del>	
<del>BE</del>	<del>345</del>	<del>Mellits, K.H., et al., "Proteolytic degradation of MAD3 (I<math>\kappa</math>B <math>\alpha</math>) and enhanced processing of the NF-<math>\kappa</math>B precursor p105 are obligatory steps in the activation of NF-<math>\kappa</math>B", Nucleic Acids Research, Volume 21, Number 22, pages 5059-5066 (1993)</del>	
<del>BE</del>	<del>346</del>	<del>Miyamoto, S., et al., "Tumor necrosis factor <math>\alpha</math>-induced phosphorylation of I<math>\kappa</math>B <math>\alpha</math> is a signal for its degradation but not dissociation from NF-<math>\kappa</math>B", Proceedings of the National Academy of Sciences USA, Volume 91, pages 12740-12744 (1994)</del>	
<del>BE</del>	<del>386</del>	<del>Read, M.A., et al., "The Proteasome Pathway is Required for Cytokine-Induced Endothelial-Leukocyte Adhesion Molecule Expression", Immunity, Volume 2, pages 493-506 (1995)</del>	
<del>BE</del>	<del>390</del>	<del>Siebenlist, U., et al., "Structure, Regulation and Function of NF-<math>\kappa</math>B", Annual Review of Cell Biology, Volume 10, pages 405-455 (1994)</del>	
<del>BE</del>	<del>392</del>	<del>Thanos, D. and Maniatis, T., "NF-<math>\kappa</math>B: A Lesson in Family Values", Cell, Volume 80, pages 529-532 (1995)</del>	
<del>BE</del>	<del>393</del>	<del>Thevenin, C., et al., "Induction of Nuclear Factor-<math>\kappa</math>B and the Human Immunodeficiency Virus Long Terminal Repeat by Okadaic Acid, a Specific Inhibitor of Phosphatases 1 and 2A", New Biologist, Volume 2, Number 9, pages 793-800 (1990)</del>	

*C. N. Allen*

*3/6/00*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/052005-10/8/02/297
		Filing Date	January 17, 2002
		First Named Inventor	Chen, Zhijian J.
		Group Art Unit	1652
		Examiner Name	Patterson, Charles L., Jr.
		Attorney Docket Number	MPI96-031CP1DV1CPACN1M
Sheet	4	of	5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
	345	Traenckner, E.B., et al., "Phosphorylation of Human IκB-α on Serines 32 and 36 Controls IκB-α Proteolysis and NF-κB Activation in Response to Diverse Stimuli", The EMBO Journal, Volume 14, Number 12, pages 2876-2883 (1995)	012 2/10/02 Page 1
	58	Yang, Y.-L., et al., "Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase", The EMBO Journal, Volume 14, Number 24, pages 6095-6106 (1995)	
CN	54	Xu, S., et al., "Cloning of rat MEK kinase 1 cDNA reveals an endogenous membrane-associated 195-kDa protein with a large regulatory domain", Proceedings of the National Academy of Sciences USA, Volume 93, pages 5291-5295 (1996)	
	42	Khoshnasan, A., et al., "The Physical Association of Protein Kinase Cθ with a Lipid Raft-Associated Inhibitor of IκB Factor Kinase (IKK) Complex Plays a Role in the Activation of the NF-κB Cascade by TCR and CD28", The Journal of Immunology, Volume 165, pages 6933-6940 (2000)	
	50	DiDonato, J.A., et al., "A Cytokine-responsive IκB kinase that Activates the Transcription Factor NF-κB", Nature, Volume 388, pages 548-554 (August 1997)	
	40	Miller, B.S. and Zandi, E., "Complete Reconstitution of Human IκB Kinase (IKK) Complex in Yeast", The Journal of Biological Chemistry, Volume 276, Number 39, pages 36320-36326 (September 28, 2001)	
	50	Fu, D.-X., et al., "Human T-lymphotropic Virus Type I Tax Activates I-κB Kinase by Inhibiting I-κB Kinase-associated Serine/Threonine Protein Phosphatase 2A", The Journal of Biological Chemistry, Volume 278, Number 3, pages 1487-1493 (January 17, 2003)	
	50	Storz, P. and Toker, A., "Protein kinase D mediates a stress-induced NF-κB Activation and Survival Pathway", The EMBO Journal, Volume 22, Number 1, pages 109-120 (2003)	
CN	40	Yang, J., et al., "The Essential Role of MEKK3 in TNF-induced NF-κB Activation", Nature Immunology, Volume 2, Number 7, pages 620-624 (July 2000)	

*Mattison* 5/8/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/052005 10/8/00, 243
		Filing Date	January 17, 2002
		First Named Inventor	Chen, Zhijian J.
		Group Art Unit	1652
		Examiner Name	Patterson, Charles L., Jr.
Sheet 5 of 5	Attorney Docket Number	MPI98-031CP1DV1CPACN1M	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T*
CP	BS	Zhao, Q. and Lee, F.S., "Mitogen-activated Protein Kinase/ERK Kinase Kinases 2 and 3 Activate Nuclear Factor-kB through IκB Kinase-α and IκB Kinase-β", The Journal of Biological Chemistry, Volume 274, Number 13, pages 8355-8358 (March 26, 1999)	
	BT	Tojima, Y., et al., "NAK is an IκB kinase-activating kinase", Nature, Volume 404, pages 778-782 (April 13, 2000)	
	BK	Wang, C., et al., "TAK1 is a Ubiquitin-dependent kinase of MKK and IKK", Nature, Volume 412, pages 346-351 (July 19, 2001)	
	BV	Regnier, C.H., et al., "Identification and Characterization of an IκB Kinase", Cell, Volume 90, pages 373-383 (July 25, 1997)	
CP	BU	Connelly, M.A. and Marcu, K.B., "CHUK, A New Member of the Helix-loop-helix and Leucine Zipper Families of Interacting Proteins, Contains a Serine-Threonine Kinase Catalytic Domain", Cellular and Molecular Biology Research, Volume 41, Number 6, pages 537-549 (1995)	

Examiner Signature	<i>CP Patterson</i>	Date Considered	5/8/06
--------------------	---------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Unique citation design number. \*Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	5/8/06
-----------------------	---	--------------------	--------

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-98)

Approved for use through 10/31/99. OMB 0854-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/810,793
		Filing Date	March 26, 2004
		First Named Inventor	Chen, Zhijian J.
		Group Art Unit	1652
		Examiner Name	Patterson, Charles L., Jr.
		Attorney Docket Number	MPI96-031CP1DV1CPACN2M
Sheet	1	of	1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
CP	F13	Tamaoki, T., et al., "Staurosporine, a potent inhibitor of phospholipids/Ca++ dependent protein kinase," <i>Biochemical and Biophysical Research Communications</i> , Vol. 135, Issue 2 (March 1986) pp 397-402	
C	F14	Kase, H., et al., "K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases," <i>Biochemical and Biophysical Research Communications</i> , Vol. 142, Issue 2 (January 1987) pp 436-440	
CP	F15	Segel, I.H., <i>Enzyme Kinetics</i> (1975) pp 89-96	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

CP

5/8/06